Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
A phase 3 trial testing AAA817 in prostate cancer, now recruiting.
Overview
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC is a phase 3 interventional study registered as NCT06855277, led by Novartis Pharmaceuticals, and recruiting when checked on 2026-09-11. Official title: A Phase III, Open-label, Multi-centre, Randomised Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer. Planned enrolment is 940 participants (estimated). The study started in 2025-07-01 and primary completion is expected in 2028-09-29. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialOpen-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Shares AAA817, Novartis, Prostate cancer and the tag ctgov-ingest.
- TrialStudy of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
Shares Novartis and the tag ctgov-ingest.
- TrialAn Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Shares Novartis and the tag ctgov-ingest.
- TrialSaruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Shares Prostate cancer and the tag ctgov-ingest.
- TrialA Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Shares Prostate cancer and the tag ctgov-ingest.
- TrialStudy of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Shares Prostate cancer and the tag ctgov-ingest.
- TrialA Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Shares Prostate cancer and the tag ctgov-ingest.
- TrialA Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Shares Prostate cancer and the tag ctgov-ingest.